
Today on Drug Discovery & Development
NIH is reorganizing clinical trial funding by trial type instead of disease
The National Institutes of Health (NIH) is planning a suite of five cross-institute trial Notices of Funding Opportunity (NOFOs) that it says would give investigators one set of instructions per trial type. On Nov. 10, NIH said its institutes are jointly building broad clinical trial NOFOs organized by trial type. Historically, many institutes wrote their…Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Design
by Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator safety. Among the many variables that must be tightly controlled, pressure ranks high on the list. Overpressure or vacuum conditions can compromise not only equipment, but also batch sterility, production timelines, and…Drug Discovery and Development See More >

Unlocking PROTAC potential through better delivery
PROTACs (proteolysis-targeting chimeras) are an emerging class of drug molecules designed to eliminate disease-causing proteins rather than simply block them. Each PROTAC has two binding ends joined by a chemical linker: one end attaches to the target protein, while the other recruits an E3 ubiquitin ligase, an enzyme that tags proteins for disposal. By bringing…

2026 PharmSci 360 adds tracks on research credibility and post-animal drug development

FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide

As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%

Sai Life Sciences’ bet on information-dense scale-up and how it is responding to pharma clients who want acceleration
Sponsored Content See More >
Genomics/Proteomics See More >

New cell imaging method reveals hidden enzyme activity
Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…

Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification

Spatial biology: Transforming our understanding of cellular environments

Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Infectious Disease See More >

After six years in stealth, Humanitas bets on hybrid AI for drug discovery
Humanitas Global Health launched at AAPS PharmSci 360 with LSU’s DeepDrug, which pairs an LLM with a hypergraph for drug design and prescription safety.

Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3

Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice

AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.

FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life
Oncology See More >

Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
Insilico’s AI-designed pan-TEAD inhibitor ISM6331 produced responses in 4 of 22 pretreated mesothelioma patients; a Phase 2a is planned for 2027.

What real-world data shows about current cancer care

Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront

After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice

























